Drug pricing has become a hot-button political issue in American politics over the past several years, featuring prominently in the 2016 presidential campaign, and remaining in national news in the early days of the Trump Administration. Despite its national profile, the lion’s share of the legislative action on this issue is taking place at the state level. In particular, there has been a significant push in states to require what policymakers describe as increased “transparency” in how drug prices and price increases are set. These proposals have come in many forms and in numerous states. In June 2016, Vermont Governor Peter Shumlin signed the first such piece of legislation into law. Already in the 2017 legislative session, there have been numerous efforts to enact similar bills in statehouses across the country and in Congress.
The primary focus of this blog will be to track the progress of major pieces of state drug pricing legislation and related bills, and to highlight certain key features of these proposals as they evolve through state legislatures. In addition, we will address noteworthy federal legislative developments and corporate pronouncements related to prescription drug pricing, such as commitments by major drug manufacturers on price increases and transparency. We hope that this blog will be as a valuable resource to healthcare stakeholders and others interested in following current developments in prescription drug policy.
We would love to hear from you, so please don’t hesitate to contact us.
Other Foley Hoag Blogs
- Advertising & Marketing Law
- Corporate Social Responsibility and the Law
- Energy & Cleantech Counsel
- IPO, Then What?
- Law and the Environment
- Massachusetts Labor & Employment Law
- Massachusetts Marijuana Counsel
- Massachusetts Noncompete Law
- Medicaid and the Law
- Security, Privacy & The Law
- State AG Insights
- Trademark and Copyright Law Blog